- Report
- May 2024
- 181 Pages
Global
From €4672EUR$4,900USD£4,004GBP
- Report
- May 2024
- 180 Pages
Global
From €4672EUR$4,900USD£4,004GBP
- Report
- February 2024
- 116 Pages
Global
From €4529EUR$4,750USD£3,882GBP
- Report
- October 2023
Asia Pacific
From €1430EUR$1,500USD£1,226GBP
- Report
- October 2023
- 75 Pages
India
From €3337EUR$3,500USD£2,860GBP
- Report
- January 2022
- 115 Pages
Global
From €4529EUR$4,750USD£3,882GBP
- Report
- January 2022
- 193 Pages
Global
From €3433EUR$3,600USD£2,942GBP
- Report
- March 2021
Middle East, Africa, ... Middle East, Africa, Asia Pacific, Latin America
From €4291EUR$4,500USD£3,678GBP
- Book
- July 2018
- 376 Pages
- Book
- October 2023
Global
- Book
- December 2020
- 672 Pages
- Book
- November 2019
- 416 Pages
- Book
- February 2019
- 480 Pages
- Book
- April 2013
- 720 Pages
- Book
- June 2021
- 672 Pages
Global
The Vector Borne Disease market is a subset of the healthcare services industry that focuses on the prevention, diagnosis, and treatment of diseases that are spread by vectors such as mosquitoes, ticks, and fleas. Vector Borne Diseases (VBDs) are a major public health concern, as they can cause serious illnesses and even death. The market is composed of a variety of stakeholders, including healthcare providers, public health organizations, and pharmaceutical companies.
The market is driven by the need to reduce the burden of VBDs on public health systems, as well as the development of new treatments and vaccines. Governments and other organizations are investing in research and development to improve the diagnosis and treatment of VBDs.
Some of the major players in the Vector Borne Disease market include Sanofi, GlaxoSmithKline, Merck, Pfizer, and Novartis. These companies are involved in the development of vaccines, treatments, and diagnostics for VBDs. Additionally, there are a number of smaller companies that are involved in the research and development of VBDs. Show Less Read more